RU2012114261A - ANALGETIC PRODUCT BASED ON PLASMID DNA - Google Patents
ANALGETIC PRODUCT BASED ON PLASMID DNA Download PDFInfo
- Publication number
- RU2012114261A RU2012114261A RU2012114261/10A RU2012114261A RU2012114261A RU 2012114261 A RU2012114261 A RU 2012114261A RU 2012114261/10 A RU2012114261/10 A RU 2012114261/10A RU 2012114261 A RU2012114261 A RU 2012114261A RU 2012114261 A RU2012114261 A RU 2012114261A
- Authority
- RU
- Russia
- Prior art keywords
- plasmid dna
- defensin
- analgesic
- analgetic
- gene
- Prior art date
Links
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
1. Анальгетическое средство на основе плазмидной ДНК, с которой в клетках млекопитающих экспрессируется ген дефенсина NP-1, либо модифицированный для увеличения собственной экспрессии ген дефенсина NP-1.2. Анальгетическое средство по п.1 для введения в организм человека и млекопитающих с целью снятия болевого синдрома любой этиологии.3. Анальгетическое средство по п.1, характеризующееся тем, что получено с использованием методов молекулярной биологии, микробиологии и рекомбинантных ДНК, т.е. не является синтетическим.1. An analgesic agent based on plasmid DNA, with which the defensin NP-1 gene is expressed in mammalian cells, or the defensin NP-1.2 gene modified to increase intrinsic expression. The analgesic according to claim 1 for the introduction into the human body and mammals in order to relieve pain of any etiology. The analgesic according to claim 1, characterized in that it is obtained using methods of molecular biology, microbiology and recombinant DNA, i.e. not synthetic.
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2012114261/10A RU2012114261A (en) | 2012-04-10 | 2012-04-10 | ANALGETIC PRODUCT BASED ON PLASMID DNA |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2012114261/10A RU2012114261A (en) | 2012-04-10 | 2012-04-10 | ANALGETIC PRODUCT BASED ON PLASMID DNA |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2012114261A true RU2012114261A (en) | 2013-10-20 |
Family
ID=49356902
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2012114261/10A RU2012114261A (en) | 2012-04-10 | 2012-04-10 | ANALGETIC PRODUCT BASED ON PLASMID DNA |
Country Status (1)
Country | Link |
---|---|
RU (1) | RU2012114261A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2597789C2 (en) * | 2014-11-10 | 2016-09-20 | Илья Владимирович Духовлинов | Analgetic agent on the basis of plasmid dna coding hnp-1, or hnp-2, or hnp-3 (versions) |
-
2012
- 2012-04-10 RU RU2012114261/10A patent/RU2012114261A/en unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2597789C2 (en) * | 2014-11-10 | 2016-09-20 | Илья Владимирович Духовлинов | Analgetic agent on the basis of plasmid dna coding hnp-1, or hnp-2, or hnp-3 (versions) |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112015024605A2 (en) | systems and methods for targeted therapeutic protein production within target cells | |
CY1121217T1 (en) | METHODS FOR HARVESTING MAMMAL CELL CULTURES | |
EA201400993A1 (en) | ANTIBODIES AGAINST THE EPIDERMAL GROWTH FACTOR RECEPTOR, ACTIVE IN CERTAIN CONDITIONS AND METHODS OF THEIR APPLICATION | |
WO2016106404A3 (en) | Methods and compositions for treating malignant tumors associated with kras mutation | |
EA201491470A1 (en) | COMPOSITIONS OF FACTOR VIII AND METHODS OF OBTAINING AND USING SIMILAR | |
EA201792441A2 (en) | FIBRONECTIN TYPE III DOMAINS CONNECTING WITH A PROSTATSPECIFIC MEMBRANE ANTIGEN | |
MX2018010529A (en) | Compositions and methods for the improved production and delivery of rna by efficient transcription termination. | |
BR112015014752A2 (en) | compounds and methods for kinase modulation, and indications for this | |
MX2013003681A (en) | Engineered nucleic acids and methods of use thereof. | |
EA201490627A1 (en) | COMPOUNDS FOR IMPROVED VIRAL TRANSDUCTION | |
BR112013023774A2 (en) | glycosylceramide synthase inhibitors | |
MX2016005824A (en) | Cell culture method. | |
AR092879A1 (en) | G3P FUSION PROTEINS AS AGENTS OF UNION TO AMILOIDE | |
MX2018003757A (en) | Compositions and methods for producing dendritic cells. | |
BR112014002173A2 (en) | purified proteins | |
GB201013215D0 (en) | Expression of antibody or a fragment thereof in lactobacillus | |
MY180183A (en) | Methods and compositions for preventing norleucine misincorporation into proteins | |
EA202190727A3 (en) | RECOMBINANT NUCLEIC ACID, VECTOR CONTAINING IT, AND METHOD FOR CELL TRANSFECTION | |
MX2018010196A (en) | Targeted therapeutic lysosomal enzyme fusion proteins, associated formulations and uses thereof. | |
MX2019005693A (en) | Red blood cell targeted factor viii and method of using the same. | |
RU2012114261A (en) | ANALGETIC PRODUCT BASED ON PLASMID DNA | |
MX350005B (en) | Pentose fermenting microorganisms. | |
EA201791442A1 (en) | METHODS OF TREATMENT OF HEMATOLOGICAL DISTURBANCES, SOLID TUMORS OR INFECTIOUS DISEASES WITH THE USE OF NATURAL CELL-CALLERS | |
MX2017013206A (en) | Optimized nucleotide sequence and pharmaceutical composition based thereon with prolonged vegf transgene expression. | |
EA201790642A1 (en) | ALLEL-SPECIFIC THERAPY FOR HAPLOTYPES OF HANTINGTON'S DISEASE |